H.C. Wainwright reiterates Connect Biopharma stock rating at buy

H.C. Wainwright maintained its "Buy" rating and set a $7.00 price target for Connect Biopharma Holdings Ltd (NASDAQ:CNTB). The stock is currently trading at $2.04, below the analyst consensus range of $4 to $10. The firm's positive outlook stems from the upcoming Seabreeze STAT asthma and COPD trial data, which is anticipated to be released soon.

Connect Biopharma's key opinion leader emphasized that treatment failure, including recurrent exacerbations and repeat acute-care utilization, is the most clinically meaningful measure of success. A 30% relative reduction would be considered a meaningful win, while 40% would be deemed a strong outcome and 50% an especially compelling result.

H.C. Wainwright believes that rademikibart, the company's drug candidate, should be primarily assessed on its ability to reduce treatment failure over 28 days, as this is the key metric that physicians care about in practice. The firm also noted that Connect Biopharma holds more cash than debt and maintains a current ratio of 2.37, although the stock appears slightly overvalued at current levels.

Other recent analyst reports include Canaccord's Buy rating with a $7.00 price target and Oppenheimer's Outperform rating with an $8.00 price target, both anticipating results from the Phase II Seabreeze STAT program for acute respiratory conditions.